Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.40 EUR
82.53 M EUR
221.81 M EUR
11.31 M
About Basilea Pharmaceutica AG
Sector
Industry
CEO
David Veitch
Website
Headquarters
Allschwil
Founded
2000
ISIN
CH0011432447
FIGI
BBG00FGWT9X1
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PK5 is 49.15 EUR — it has increased by 1.24% in the past 24 hours. Watch Basilea Pharmaceutica AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Basilea Pharmaceutica AG stocks are traded under the ticker PK5.
PK5 stock has risen by 33.97% compared to the previous week, the month change is a 33.97% rise, over the last year Basilea Pharmaceutica AG has showed a 34.66% increase.
We've gathered analysts' opinions on Basilea Pharmaceutica AG future price: according to them, PK5 price has a max estimate of 112.49 EUR and a min estimate of 60.74 EUR. Watch PK5 chart and read a more detailed Basilea Pharmaceutica AG stock forecast: see what analysts think of Basilea Pharmaceutica AG and suggest that you do with its stocks.
PK5 stock is 1.75% volatile and has beta coefficient of 1.06. Track Basilea Pharmaceutica AG stock price on the chart and check out the list of the most volatile stocks — is Basilea Pharmaceutica AG there?
Yes, you can track Basilea Pharmaceutica AG financials in yearly and quarterly reports right on TradingView.
Basilea Pharmaceutica AG is going to release the next earnings report on Feb 17, 2026. Keep track of upcoming events with our Earnings Calendar.
PK5 earnings for the last half-year are 1.35 EUR per share, whereas the estimation was 2.17 EUR, resulting in a −37.93% surprise. The estimated earnings for the next half-year are 1.85 EUR per share. See more details about Basilea Pharmaceutica AG earnings.
Basilea Pharmaceutica AG revenue for the last half-year amounts to 111.28 M EUR, despite the estimated figure of 105.07 M EUR. In the next half-year revenue is expected to reach 129.53 M EUR.
PK5 net income for the last half-year is 16.91 M EUR, while the previous report showed 60.47 M EUR of net income which accounts for −72.04% change. Track more Basilea Pharmaceutica AG financial stats to get the full picture.
No, PK5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 30, 2025, the company has 164 employees. See our rating of the largest employees — is Basilea Pharmaceutica AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Basilea Pharmaceutica AG EBITDA is 85.20 M EUR, and current EBITDA margin is 31.03%. See more stats in Basilea Pharmaceutica AG financial statements.
Like other stocks, PK5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Basilea Pharmaceutica AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Basilea Pharmaceutica AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Basilea Pharmaceutica AG stock shows the buy signal. See more of Basilea Pharmaceutica AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.